Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 23.10.2026 UNCU.LN IE00BD6GCF16 1,021,951.00 USD  51,811,409.06   50.699  ...

SINGAPORE & MILAN--(BUSINESS WIRE)--TVS Motor Company returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition....

NEW YORK--(BUSINESS WIRE)--Moonshot AI's Kimi K3.1 Pro got 86.1% of tasks right on the DualEntry Accounting AI Benchmark, placing fourth and ahead of every model from Anthropic, OpenAI and Meta. With Zhipu AI's GLM-5.3 Flash tied for second at 88.1%, two of the top four models are now open. The gap at the top is three points. Google's Gemini 4 Argon leads at 91.1%, and the best open model trails it by 3.0 points. Across the leaderboard, the seven open models average 83.9%, while the 13 closed m...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointments of David Acheson as Chief Commercial Officer and Brian Newkirk as Chief Business Officer. The appointments strengthen Brixton's executive leadership team as the Company prepares for potential commercialization of its lead product, Reneurx™ Nerve-Sele...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Turning Point Brands, Inc. (NYSE: TPB) announced the date and time for its conference call to review third quarter 2026 results. The conference call will be on Monday, November 9th at 9:00 a.m. Eastern Time. Webcast Link: https://events.q4inc.com/attendee/633308822 Analyst Dial-ins: North America (Toll-Free): +1 833 461 5787 International (Toll): +1 585 542 9983 International Dial-Ins Meeting ID: 633 308 822 Analyst Pre-Registration Link The registration link e...

BOSTON--(BUSINESS WIRE)--Silversmith Capital Partners, a growth equity firm focused on supporting the best entrepreneurs in technology and healthcare, today announced the appointment of Jean Gulliver as Head of Investor Relations. In this role, Jean will lead the firm’s institutional investor relationships and capital formation efforts. “Jean is someone I’ve known and respected for years, and we couldn’t be more excited to welcome her to Silversmith,” said Lori Whelan, Managing Partner & CO...

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced the voting results from its annual general and special meeting of shareholders convened on September 25, 2026, and adjourned to and reconvened on October 23, 2026 (the “Meeting”). A total of 154,837,897 common shares of the Company (the “Shares”), representing 36.60% of...

GENEVA--(BUSINESS WIRE)--Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented updated long-term results from a Phase 1/1b study of NI-1801 as a monotherapy and in combination with pembrolizumab in heavily pretreated Platinum Resistant Ovarian Cancer (PROC) patients that have no approved standard of care treatment. The data were reported in a Poster presentation at European Society of Medical Oncolo...

GENÈVE--(BUSINESS WIRE)--Light Chain Bioscience, société de biotechnologie Suisse en phase clinique qui développe la prochaine génération d’anticorps bispécifiques pour le traitement du cancer, a présenté aujourd’hui des résultats actualisés à long terme d’une étude de phase 1/1b évaluant NI-1801 en monothérapie et en association avec le pembrolizumab chez des patientes lourdement prétraitées atteintes d’un cancer de l’ovaire résistant au platine (PROC), pour lesquelles il n’existe aucun traite...

GENF--(BUSINESS WIRE)--Light Chain Bioscience, ein Schweizer klinisches Biotechnologieunternehmen, das die nächste Generation bispezifischer Antikörper zur Krebsbehandlung vorantreibt, hat heute aktualisierte Langzeitergebnisse einer Phase-1/1b-Studie zu NI-1801 als Monotherapie und in Kombination mit Pembrolizumab bei stark vorbehandelten Patientinnen mit platinresistentem Ovarialkarzinom (PROC) vorgestellt, für die keine zugelassene Standardtherapie existiert. Die Daten wurden in einer Poster...